BACKGROUND: Treatment of @entity6691 suppurativa (HS) is difficult and the search for effective therapies continues. OBJECTIVES: 1.To evaluate the efficacy of ustekinumab. 2.To discover a potential biomarker. METHODS: Seventeen @entity1 were included in this open label study and treated with 45 to 90 mg ustekinumab at weeks 0, 4, 16 and 28. Proteomic technology and enzyme-linked assay analysis (ELISA) was applied on serum. RESULTS: Twelve @entity1 completed the protocol. Moderate to marked improvement of the modified Sartorius Score was achieved in 82% of @entity1 at week 40 and the @entity6691 suppurativa clinical response (HiSCR-50) in 47%. At baseline, a significant difference was observed in the expression of 54 serum proteins between @entity1 and healthy controls. Involved pathways were related to @entity32 , immune cell signaling, and tissue morphology/development. Good responders had milder disease and lower expression of @entity19960 ( @entity19960 ). @entity2902 , @entity310 , @entity4155 and @entity4654 were not elevated and did not change during treatment. CONCLUSIONS: The majority of @entity1 improved with ustekinumab. Although no biomarker was discovered, low @entity19960 concentrations with mild disease severity may be predictive for the effectiveness of ustekinumab. This article is protected by copyright. All rights reserved.

Ustekinumab in XXXX suppurativa: clinical results and a search for potential biomarkers in serum.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity32 :: ('MESH:D007249', 'Disease') :: ['inflammation'] @entity310 :: ('7124', 'Gene') :: ['TNF-a'] @entity4155 :: ('3605', 'Gene') :: ['IL17A'] @entity4654 :: ('112744', 'Gene') :: ['IL-17F'] @entity2902 :: ('3559', 'Gene') :: ['IL-2R'] @entity19960 :: ('4048', 'Gene') :: ['leukotriene A4-hydrolase', 'LTA4H'] @entity6691 :: ('MESH:D016575', 'Disease') :: ['hidradenitis']
@entity6691 :: (MESH:D016575,Disease) :: ['hidradenitis']
